Patients with coronavirus disease 2019 (COVID-19) are reported to have a greater
prevalence of hyperglycaemia. Cytokine release as a consequence of severe acute …

Purpose To assess whether dysglycemia diagnosed during severe acute respiratory
syndrome coronavirus 2 pneumonia may become a potential public health problem after …

Background Identification of risk factors of severe coronavirus disease 2019 (COVID‐19) is
critical for improving therapies and understanding severe acute respiratory syndrome …

COVID-19 is an acronym formed by ''CO''for corona,''VI''for virus, and ''D''for disease. The
''19''represents 2019—the year when the infection started. This new disease was unknown …

The COVID-19 pandemic has stretched healthcare resources and caused severe knock-on
effects on patients with metabolic diseases worldwide. We encourage clinicians and patient …

Summary Type 2 diabetes (T2D) is a major comorbidity of COVID-19. However, the impact of
blood glucose (BG) control on the degree of required medical interventions and on mortality …

Acutely ill patients present often with hyperglycemia (caused among other factors by
endogenous stress-induced glucocorticoid hypersecretion)[1]. In preliminary reports …

The prevalence of COVID-19-associated diabetes is not the result of a single event but of a
combination of disease susceptibility associated with chronic illness and COVID-19-specific …

We agree with the conclusion by Dr. Hill and colleagues in their commentary “COVID-19 in
Patients with Diabetes”, that for patients with COVID-19 infections, the presence of diabetes …

COVID-19 is a disease caused by the coronavirus SARS-CoV-2 (Severe Acute Respiratory
Syndrome Coronavirus-2), known as a highly contagious disease, currently affecting more …